HCP
JAZZ icon

Hexagon Capital Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

Hexagon Capital Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2
Closed -$248 – 913
2025
Q1 		$248 Hold
2
– – ﹤0.01% 1733
2024
Q4 		$246 Buy
+2
New +$236 ﹤0.01% 1752

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Hexagon Capital Partners's JAZZ Position: Q2 2025 in Review

Hexagon Capital Partners sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2025, closing a stake of 2 shares — an estimated $248 sold.

Hexagon Capital Partners first reported a position in JAZZ in Q4 2024 and held it in 2 quarters. The position peaked at $248 in Q1 2025. 501 funds tracked by Wall St. Rank hold JAZZ as of Q2 2025.

  • Hexagon Capital Partners reported no remaining Jazz Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Hexagon Capital Partners sold 2 Jazz Pharmaceuticals shares in Q2 2025, an estimated $248.
  • Hexagon Capital Partners first reported a position in Jazz Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • Hexagon Capital Partners's Jazz Pharmaceuticals position peaked at $248 in Q1 2025.
  • 501 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2025.

Based on Hexagon Capital Partners's 13F filing for Q2 2025, filed 11 Aug 2025.